First-in-man single ascending dose study with an oral solution of EV-077.

Trial Profile

First-in-man single ascending dose study with an oral solution of EV-077.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2012

At a glance

  • Drugs SER 150 (Primary)
  • Indications Arterial thrombosis; Cardiovascular disorders
  • Focus Adverse reactions
  • Sponsors Evolva SA
  • Most Recent Events

    • 20 Jul 2012 Results published in the European Journal of Clinical Pharmacology.
    • 16 Dec 2010 Status changed from recruiting to completed, as reported in and Evolva media release.
    • 16 Jul 2009 Single ascending dose portion of the trial completed, as reported by Evolva Biotech. The multiple ascending dose phase will be conducted next.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top